Carrington Louise M, Albon Julie, Anderson Ian, Kamma Christina, Boulton Mike
Cell and Molecular Unit, School of Optometry and Vision Sciences, Cardiff University, Cardiff, United Kingdom.
Invest Ophthalmol Vis Sci. 2006 May;47(5):1886-94. doi: 10.1167/iovs.05-0635.
Inhibition of TGF-beta reduces myofibroblast differentiation and fibrosis in the cornea. Determining the actions of distinct TGF-beta isoforms and their inhibitors during early corneal wound healing is an essential step in guiding therapeutic intervention.
Bovine serum-free corneal cell and wounded organ cultures were challenged with a range of concentrations of TGF-beta1, -beta2, and -beta3; IL-10; and neutralizing human monoclonal antibodies (mAbs) against TGF-beta1 (CAT-192) or -beta2, (CAT-152). Cultures were assessed for re-epithelialization, proliferation (cell counts and cresyl violet assay), morphology (histologic examination), repopulation of the area under the wound, and myofibroblast transformation (alpha-smooth muscle actin) between 0 and 5 days.
TGF-beta1 delayed re-epithelialization, increased repopulation of the stroma, increased keratocyte proliferation and was the only isoform to promote myofibroblast differentiation. The anti-TGF-beta1 mAb, CAT-192 promoted re-epithelialization and reduced repopulation of the stroma. Exogenous TGF-beta3 had little effect on re-epithelialization but reduced repopulation of the stroma. IL-10 promoted corneal re-epithelialization at low doses but inhibited this response at high doses. Stromal repopulation was prevented by all doses of IL-10. TGF-beta2 or the anti-TGF-beta2 mAb, CAT-152 had little effect on any repair parameter.
The results confirm TGF-beta1 as the principal isoform in corneal wound healing and suggest that inhibition of the action of TGF-beta1 can promote corneal wound healing. Treatment with the anti-TGF-beta1 mAb CAT-192 accelerates corneal re-epithelialization but reduces cell repopulation of the stroma. The cytokines TGF-beta3 and IL-10 have opposing actions to that of TGF-beta1.
抑制转化生长因子-β(TGF-β)可减少角膜中肌成纤维细胞的分化和纤维化。确定不同TGF-β亚型及其抑制剂在角膜早期伤口愈合过程中的作用是指导治疗干预的关键步骤。
用一系列浓度的TGF-β1、-β2和-β3、白细胞介素-10(IL-10)以及针对TGF-β1(CAT-192)或-β2(CAT-152)的中和人单克隆抗体(mAb)对无牛血清的角膜细胞和受伤器官培养物进行刺激。在0至5天之间评估培养物的再上皮化、增殖(细胞计数和甲酚紫测定)、形态(组织学检查)、伤口下方区域的细胞再填充以及肌成纤维细胞转化(α-平滑肌肌动蛋白)情况。
TGF-β1延迟了再上皮化,增加了基质的细胞再填充,增加了角膜细胞增殖,并且是促进肌成纤维细胞分化的唯一亚型。抗TGF-β1 mAb CAT-192促进了再上皮化并减少了基质的细胞再填充。外源性TGF-β3对再上皮化影响不大,但减少了基质的细胞再填充。低剂量的IL-10促进角膜再上皮化,但高剂量时抑制这种反应。所有剂量的IL-10都可阻止基质的细胞再填充。TGF-β2或抗TGF-β2 mAb CAT-152对任何修复参数影响不大。
结果证实TGF-β1是角膜伤口愈合中的主要亚型,并表明抑制TGF-β1的作用可促进角膜伤口愈合。用抗TGF-β1 mAb CAT-192治疗可加速角膜再上皮化,但减少基质的细胞再填充。细胞因子TGF-β3和IL-10与TGF-β1的作用相反。